Barrett??s surveillance is worthwhile and detects curable cancers. A prospective cohort study addressing cancer incidence, treatment outcome and survival

Aldulaimi, David; Cox, M. A.; Nwokolo, Chuka U.; Loft, Duncan E.

doi:10.1097/00042737-200509000-00010

Cited by 48 publications

(41 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…13 The true annual incidence of EAC in BE patients remains unclear, as it shows considerable variation among cohort studies, ranging from 0.2% to almost 3.5% per year. 14,15 These rates could have been overestimated as a result of publication bias in published BE surveillance studies, with evidence of selective publication of small studies with high cancer incidence rates. 16 In addition, some studies have reported an overall increased mortality in BE patients compared with the general population, 17,18 whereas others could not confirm this.…”

mentioning

confidence: 99%

Risk of Esophageal Adenocarcinoma and Mortality in Patients With Barrett's Esophagus: A Systematic Review and Meta-analysis

Sikkema

Jonge

Steyerberg

et al. 2010

Clinical Gastroenterology and Hepatology

314

210

View full text Add to dashboard Cite

mentioning

confidence: 99%

Risk of Esophageal Adenocarcinoma and Mortality in Patients With Barrett's Esophagus: A Systematic Review and Meta-analysis

Sikkema

Jonge

Steyerberg

et al. 2010

Clinical Gastroenterology and Hepatology

314

210

View full text Add to dashboard Cite

“…The true annual incidence of EAC in BE patients is unclear because cohort studies have shown considerable variation, ranging from 0.2-3.5 % per year [58,59]. As Sikkema et al [60] pointed out, however, these rates could have been overestimated as a result of publication bias in published BE surveillance studies, with evidence of a selective publication of small studies with high cancer incidence rates [44].…”

Section: Risk Factors For Eac or Dysplasiamentioning

confidence: 99%

Carcinogenesis of Barrett’s esophagus: a review of the clinical literature

Watari

Oshima

Fukui

et al. 2013

Clin J Gastroenterol

View full text Add to dashboard Cite

Barrett's esophagus (BE) is a premalignant condition of esophageal adenocarcinoma (EAC). Although the incidence of BE has risen rapidly in the West, it is rare in Asia despite a recent increase in the prevalence of gastroesophageal reflux disease. Controversies over the definition of BE are presented because most cases show shortsegment BE, especially ultra-short BE, in Asia. Here we review possible risk factors for the development of EAC, particularly possible roles of ethnicity, specialized intestinal metaplasia (SIM), BE length, and environmental factors, such as Helicobacter pylori infection and obesity. Additionally, we summarize recent studies on the effect of chemoprevention including proton pump inhibitors, nonsteroidal anti-inflammatory drugs or aspirin in order to reduce the risk of neoplastic progression in BE patients. Although substantial knowledge of risk factors of dysplasia/EAC in BE is shown, the risk for neoplastic development may be influenced by geographic variation, study population, the presence or absence of SIM or dysplasia at baseline, and the small number of BE patients investigated. Recently, the efficiency of surveillance for BE patients has been discussed from the standpoint of cost-effectiveness. It may be too difficult to draw conclusions because no randomized clinical trials of BE surveillance have been performed.

show abstract

“…Barrett's esophagus (BE), replacement of the squamous esophageal mucosa by metaplastic columnar epithelium due to prolonged reflux [6] of the gastric content into the esophagus, represents the best-known risk factor for EAC development [7] . The annual incidence of EAC development in patients with BE is 0.2%-0.5% [8,9] . Clinical and demographic factors that have shown some promise in being predictive of malignant transformation in BE are male gender [10,11] , increasing age [11] , length of Barrett's segment [12][13][14] , duration of BE [13] and size of hiatal hernia [14] .…”

Section: Introductionmentioning

confidence: 99%

Role of chemoprophylaxis with either NSAIDs or statins in patients with Barrett’s esophagus

Tsibouris

Vlachou

Isaacs

2014

WJGPT

View full text Add to dashboard Cite

The incidence of esophageal adenocarcinoma, a poor prognosis neoplasia, has risen dramatically in recent decades. Barrett's esophagus represents the best-known risk factor for esophageal adenocarcinoma development. Non-steroidal anti-inflammatory drugs through cyclooxygenase-2 inhibition and prostaglandin metabolism regulation could control cell proliferation, increase cell apoptosis and regulate the expression of growth and angiogenic factors. Statins can achieve equivalent effects through prenylation and subsequently control of cellular signaling cascades. At present, epidemiological studies are small and underpowered. Their data could not justify either medication as a chemo-preventive agent. Population based studies have shown a 43% reduction of the odds of developing an esophageal adenocarcinoma, leaving out or stating a 25% reduction in patients consuming non-aspirin nonsteroidal antiinflammatory drugs and a 50% reduction in those patients consuming aspirin. They have also stated a 19% reduction of esophageal cancer incidence when statins have been used. Observational studies have shown that non-steroidal anti-inflammatory drugs could reduce the adenocarcinoma incidence in patients with Barrett's esophagus by 41%, while statins could reduce the risk by 43%. The cancer preventive effect has been enhanced in those patients taking a combination of non-steroidal anti-inflammatory drugs and statins (a 74% decrease). Observational data are equivocal concerning the efficacy of non-steroidal anti-inflammatory drug subclasses. Non-steroidal anti-inflammatory drugs clearly have substantial potential for toxicity, while statins are rather safe drugs. In conclusion, both non-steroidal anti-inflammatory drugs and statins are promising chemopreventive agents and deserve further exploration with interventional studies. In the meanwhile, their use is justified only in patients with cardiovascular disease.© 2014 Baishideng Publishing Group Co., Limited. All rights reserved.Key words: Esophageal adenocarcinoma; Barrett's esophagus; Non-steroidal anti-inflammatory drugs; Aspirin; Statins; Cancer chemoprevention Core tip: Esophageal adenocarcinoma remains a major burden upon health. Experimental studies have suggested that non-steroidal anti-inflammatory drugs and statins may have useful actions against esophageal cancer cells. This review of observational studies shows that non-steroidal anti-inflammatory drugs reduced adenocarcinoma incidence in patients with Barrett' s esophagus by 41%, while statins reduced the risk by 43%. The cancer preventive effect is enhanced in those patients taking a combination of non-steroidal anti-inflammatory drugs and statins (a 74% decrease). Non-steroidal anti-inflammatory drugs clearly have substantial potential for toxicity, while statins are rather safe drugs. Their combination offers promise for chemoprevention and further interventional studies are warranted.Tsibouris P, Vlachou E, Isaacs PET. Role of chemoprophylaxis REVIEWOnline Submissions: http://www.wjgnet.com/esps/

show abstract

Barrett??s surveillance is worthwhile and detects curable cancers. A prospective cohort study addressing cancer incidence, treatment outcome and survival

Cited by 48 publications

References 67 publications

Risk of Esophageal Adenocarcinoma and Mortality in Patients With Barrett's Esophagus: A Systematic Review and Meta-analysis

Risk of Esophageal Adenocarcinoma and Mortality in Patients With Barrett's Esophagus: A Systematic Review and Meta-analysis

Carcinogenesis of Barrett’s esophagus: a review of the clinical literature

Role of chemoprophylaxis with either NSAIDs or statins in patients with Barrett’s esophagus

Contact Info

Product

Resources

About